CSL is currently trading at a discount, even though it owns a leading global infrastructure for plasma-derived therapies that is difficult to replicate. The company is executing a Transformation Program aiming to reduce annual pre-tax costs by $500–$550 million by fiscal year 2028, with 60% of the savings for fiscal year 2026 already achieved. Growth in the Vifor segment is strong, balancing declines in the iron franchise, while new products like ANDEMBRY and HEMGENIX are expected to drive future growth. CSL's valuation remains attractive with a forward EV/EBITDA of 10.24x and forward P/S of 2.73x, presenting a compelling opportunity for patient investors despite some temporary operational challenges.
On June 15, 2026, BlackRock, Inc. and its funds reduced their total holdings in Orion Corporation to below 5% of the company's shares and voting rights. This change was disclosed under the Finnish Securities Market Act, indicating a decrease from a p...
Autonomize, a healthcare AI platform, has strengthened its leadership by appointing three industry veterans to its Advisory Board and hiring Mike Longacre as Head of Transformation. These moves aim to help healthcare organizations move beyond AI pilo...
Fairfax Financial Holdings has finalized its acquisition of Kennedy-Wilson Holdings at $10.90 per share in cash, led by a consortium including Kennedy Wilson's CEO William McMorrow and affiliates of Fairfax. The Kennedy Wilson management team retains...
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
